Role of pegylated liposomal doxorubicin in ovarian cancer-Reference-Cited by-同舟云学术

Role of pegylated liposomal doxorubicin in ovarian cancer

Published:2005-01 Issue:1 Volume:96 Page:10-18
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Thigpen J. Tate,Aghajanian Carol A.,Alberts David S.,Campos Susana M.,Gordon Alan N.,Markman Maurie,McMeekin D. Scott,Monk Bradley J.,Rose Peter G.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference47 articles.

1. American Cancer Society. What are the key statistics about ovarian cancer? (Available at: http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_are_the_key_statistics_for_ovarian_cancer_33.asp?sitearea=&level=).

2. Cancer statistics, 2004;Jemal;CA Cancer J. Clin.,2004

3. Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma;Ozols,2001

4. Update on the management of ovarian cancer;Ozols;Cancer J.,2002

5. Advances in the management of epithelial ovarian cancer;Memarzadeh;J. Reprod. Med.,2001

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of Pegylated Liposomal Doxorubicin and CA125 Level Variability Analysis in Platinum-refractory/resistant Recurrent Ovarian Cancer;Anticancer Research;2022-05-31

2. Bionanoparticles in cancer imaging, diagnosis, and treatment;VIEW;2022-03-15

3. Horizons of nanotechnology applications in female specific cancers;Seminars in Cancer Biology;2021-02

4. Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m2 versus 40 mg/m2 in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial;Journal of Gynecologic Oncology;2021

5. Passive Targeting of Nanoparticles to Cancer;Surface Modification of Nanoparticles for Targeted Drug Delivery;2019